查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1964004

尿道感染檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用途、地區和競爭格局分類，2021-2031年

Urinary Tract Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球尿道感染檢測市場預計將從 2025 年的 6.3657 億美元成長到 2031 年的 8.1527 億美元，複合年成長率為 4.21%。

此領域涵蓋多種診斷技術，例如尿液檢查、尿液培養和分子診斷，用於識別泌尿道病原體。推動該領域發展的關鍵因素包括全球尿道感染發病率的上升，尤其是在女性和老年人群中，以及院內感染（例如導尿管相關感染）的增加。此外，對能夠實現即時治療的快速就地檢驗解決方案的迫切需求也加速了這些解決方案的普及。正如美國泌尿系統協會在2024年指出的那樣，全球每年估計發生1.5億例尿道感染，醫療保健總成本高達60億美元。

市場概覽
預測期 2027-2031
市場規模：2025年 6.3657億美元
市場規模：2031年 8.1527億美元
複合年成長率：2026-2031年 4.21%
成長最快的細分市場 膀胱炎
最大的市場 北美洲

儘管成長指標強勁，但傳統快速篩檢工具的診斷準確性仍面臨許多挑戰。傳統尿液測試紙的敏感度和特異性往往不足，導致假陰性或假陽性率較高，進而造成漏診或不必要的抗生素使用。因此，這些限制可能迫使人們依賴耗時的尿液培養檢測進行檢驗，延誤治療，並阻礙在注重成本的醫療環境中廣泛採用快速診斷方法。

市場促進因素

全球尿道感染（ UTI）發生率的不斷上升是推動市場成長的主要因素，也使得醫療機構對高通量診斷能力的需求日益成長。抗菌素抗藥性（AMR）問題的日益嚴重進一步加劇了這一需求，使得經驗性治療難以實施，因此必須準確檢測病原體以避免尿路敗血症和腎盂腎炎等併發症。隨著標準抗生素對抗藥性菌株的療效逐漸降低，臨床上越來越依賴準確的篩檢和培養確診。根據美國食品藥物管理局（FDA）2024年10月發布的關於常見感染疾病新治療方法的聲明，大約一半的女性一生中至少會經歷一次尿路感染疾病，預計對急性及復發性尿路感染診斷服務的需求將持續穩步成長。

同時，就地檢驗技術的快速發展正在革新這一領域，滿足了人們對速度和診斷準確性的迫切需求。醫療服務提供者正逐漸拋棄需要數天才能出結果的傳統方法，轉而選擇能夠即時做出臨床決策的分子檢測和快速表現型檢測。美國疾病管制與預防中心 (CDC) 於 2024 年 11 月發布的最新抗生素使用情況報告印證了這一轉變，該報告顯示，2016 年至 2023 年間，Medicare 索賠中多次分子尿道感染檢測的數量增加了 50 倍以上。此外，快速藥敏試驗技術的創新正在加速這項轉變。例如，BioMérieux 公司在 2024 年報告稱，其 VITEK REVEAL AST 系統平均可在 5.5 至 6 小時內提供某些革蘭氏陰性菌的可操作數據，從而顯著縮短標靶治療的時間。

市場挑戰

全球尿道感染檢測市場的主要障礙在於標準快速篩檢技術缺乏診斷準確性。儘管尿液測試紙檢測因其價格低廉、速度快而被廣泛應用，但其靈敏度和特異性往往不足以做出明確的醫學診斷。這種技術缺陷迫使醫護人員依賴耗時的尿液培養檢測來確認結果，從而有效地抵消了即時照護現場。因此，由於臨床醫生不能僅依賴可能存在誤差的快速診斷來製定治療決策，市場在全面過渡到分散式檢查模式方面面臨許多困難。

這種準確性的不足導致了顯著的營運效率損失和臨床風險，從而阻礙了市場成長。高頻率的假陽性結果會導致不必要的抗生素處方，而假陰性結果則會導致需要緊急治療的患者延遲治療。近期的數據凸顯了這種診斷缺陷的嚴重性。 2025年，美國泌尿系統協會報告稱，諸如白血球酯酶陽性和亞硝酸鹽陽性等標準尿液檢查標記在檢測實際感染疾病的陽性預測率低於50%。這些數據表明，目前的快速檢測工具經常無法區分真正的感染疾病和污染，迫使醫療系統維持高成本且勞動密集的參考檢查室流程，並降低了市場的整體容量。

市場趨勢

家庭和自測環境的普及正在改變全球尿道感染 ( UTI) 檢測市場，使醫療保健服務分散化，並減輕基層醫療機構的負擔。這一趨勢的特點是消費者診斷試劑盒和藥房管理的檢測服務激增，使患者無需前往全科醫生處即可獲得快速篩檢和即時治療。在推行賦能社區藥劑師政策的地區，這種轉變尤其顯著，從而在傳統醫院之外建立了一個新的高成長管道。根據《藥劑師》雜誌2025年4月報告的「藥局優先」諮詢計畫第一年的數據，2024年2月至2025年1月期間，英格蘭共進行了607,646次非複雜性尿道感染的諮詢，證實了消費者對分散式檢查管道的使用顯著增加。

同時，克服標準微生物檢測方法性能限制的需求正推動市場向分子和基因組診斷技術發生重大轉變。儘管傳統方法仍佔據主導地位，但檢測需氧微生物的難度以及快速提供抗生素敏感性數據的挑戰，正加速將次世代定序(NGS) 和先進的基因組平台應用於常規診斷。這些先進技術提高了靈敏度和特異性，能夠準確地識別傳統培養方法經常漏診的病原體。這降低了抗生素無效使用和復發性行為感染的風險。根據 Biotear 公司 2025 年 9 月發布的先進檢測服務的公告，標準尿液培養的失敗率約為 30%。這種診斷缺陷正積極推動臨床轉向更可靠的基因組為基礎的檢測解決方案。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球尿道感染檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（尿道炎、膀胱炎、腎盂腎炎）
    • 依最終用途（全科醫生、泌尿系統、泌尿系統/婦科醫生、醫院檢查室、參考檢查室、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美尿道感染檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲尿道感染檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區尿道感染檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲尿道感染檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲尿道感染檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球尿道感染檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • QIAGEN NV
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
  • BIOMeRIEUX
  • T2 Biosystems, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 21964

The Global Urinary Tract Infection Testing Market is projected to expand from USD 636.57 Million in 2025 to USD 815.27 Million by 2031, reflecting a compound annual growth rate of 4.21%. This sector includes various diagnostic techniques such as urinalysis, urine culture, and molecular diagnostics intended to identify pathogens within the urinary tract. Growth is largely driven by the increasing global incidence of urinary tract infections, especially among women and the elderly, as well as a rise in hospital-acquired cases like those associated with catheters. Additionally, the adoption of testing solutions is being hastened by the urgent need for rapid point-of-care options that enable immediate treatment. As noted by the American Urological Association in 2024, an estimated 150 million urinary tract infections occur annually worldwide, resulting in healthcare costs totaling 6 billion dollars.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 636.57 Million
Market Size 2031USD 815.27 Million
CAGR 2026-20314.21%
Fastest Growing SegmentCystitis
Largest MarketNorth America

Despite these positive growth metrics, the market encounters a substantial obstacle regarding the diagnostic precision of traditional rapid screening tools. Conventional urine dipstick tests frequently demonstrate insufficient sensitivity and specificity, causing high instances of false negatives or positives that may lead to untreated conditions or unwarranted antibiotic usage. Consequently, this limitation forces a dependence on slower urine cultures for verification, delaying appropriate therapy and potentially impeding the broader uptake of rapid diagnostic methods in cost-conscious medical environments.

Market Driver

The rising global prevalence of urinary tract infections serves as a major market propellant, creating a need for high-volume diagnostic capacities in medical facilities. This demand is further amplified by the escalating issue of antimicrobial resistance (AMR), which makes empirical treatment difficult and necessitates exact pathogen detection to avoid complications like urosepsis or pyelonephritis. As standard antibiotics lose efficacy against resistant strains, clinical reliance on accurate screening and culture confirmation has grown. According to an October 2024 announcement by the U.S. Food and Drug Administration regarding new treatments for uncomplicated infections, roughly half of all women will suffer at least one such infection during their lives, ensuring a steady and increasing demand for diagnostic services to handle acute and recurrent cases.

Concurrently, the surge in point-of-care testing technologies is revolutionizing the sector by fulfilling the urgent requirement for speed and diagnostic accuracy. Medical providers are progressively moving away from traditional techniques that take days to yield results, opting instead for molecular and rapid phenotypic tests that facilitate instant clinical decisions. This shift is highlighted by the Centers for Disease Control and Prevention's November 2024 update on antibiotic use, which noted a greater than 50-fold increase in Medicare claims for multiplex molecular urinary tract infection tests between 2016 and 2023. Additionally, innovations in rapid susceptibility testing are speeding up this transition; for instance, bioMerieux reported in 2024 that the VITEK REVEAL AST System can provide actionable data for specific gram-negative bacteria within an average of 5.5 to 6 hours, greatly improving the timeline for targeted treatments.

Market Challenge

The principal obstacle restricting the Global Urinary Tract Infection Testing Market is the inadequate diagnostic accuracy found in standard rapid screening techniques. Although urine dipstick tests are commonly used due to their affordability and speed, they often lack the sensitivity and specificity needed for conclusive medical diagnoses. This technical deficiency compels healthcare practitioners to rely on slow urine cultures to confirm findings, essentially canceling out the immediacy intended by point-of-care solutions. As a result, the market faces difficulties in fully shifting towards decentralized testing models, as clinicians are unable to trust treatment decisions exclusively to rapid diagnostics that are susceptible to errors.

This absence of precision leads to considerable operational inefficiencies and clinical dangers that inhibit market growth. High occurrences of false-positive results frequently cause unnecessary antibiotic prescriptions, whereas false negatives delay treatment for patients in need of urgent attention. The magnitude of this diagnostic shortcoming is highlighted by recent data; the American Urological Association reported in 2025 that standard urinalysis markers, such as positive leukocyte esterase and nitrites, demonstrated positive predictive values of less than 50% for detecting actual infections. Such statistics demonstrate that current rapid tools frequently fail to differentiate between genuine infection and contamination, forcing healthcare systems to sustain costly, labor-intensive reference laboratory processes that reduce overall market throughput.

Market Trends

The proliferation of home-based and self-testing environments is significantly transforming the Global Urinary Tract Infection Testing Market by decentralizing care access and reducing the pressure on primary medical facilities. This movement is defined by the growing accessibility of direct-to-consumer diagnostic kits and pharmacy-managed testing services, enabling patients to receive rapid screening and immediate therapy without visiting a general practitioner. This transition is especially apparent in areas adopting policies that empower community pharmacists, establishing a new, high-volume growth channel beyond traditional hospitals. As reported by The Pharmacist in April 2025 regarding the first year of Pharmacy First consultations, 607,646 consultations for uncomplicated urinary tract infections were conducted via the service in England between February 2024 and January 2025, underscoring substantial consumer uptake of decentralized testing routes.

At the same time, the market is undergoing a notable pivot toward molecular and genomic diagnostic techniques, motivated by the necessity to surpass the performance constraints of standard microbiological methods. While traditional practices remain prevalent, their failure to detect fastidious organisms or supply rapid antimicrobial susceptibility data has hastened the adoption of next-generation sequencing (NGS) and advanced genomic platforms in routine diagnostics. These advanced technologies provide enhanced sensitivity and specificity, allowing for the accurate identification of pathogens often missed by conventional cultures, thereby reducing the risks of ineffective antibiotic use and recurrent infections. According to a September 2025 announcement by Biotia regarding their advanced test offering, standard urine cultures fail approximately 30% of the time, a diagnostic deficiency that is actively driving the clinical shift toward more dependable genomic-based testing solutions.

Key Market Players

  • QIAGEN NV
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
  • BIOMeRIEUX
  • T2 Biosystems, Inc

Report Scope

In this report, the Global Urinary Tract Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Urinary Tract Infection Testing Market, By Type

  • Urethritis
  • Cystitis
  • Pyelonephritis

Urinary Tract Infection Testing Market, By End use

  • General Practitioners (GPs)
  • Urologists
  • Urogynecologists
  • Hospital Laboratories
  • Reference Laboratories
  • Others

Urinary Tract Infection Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Urinary Tract Infection Testing Market.

Available Customizations:

Global Urinary Tract Infection Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Urinary Tract Infection Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Urethritis, Cystitis, Pyelonephritis)
    • 5.2.2. By End use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Urinary Tract Infection Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Urinary Tract Infection Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End use
    • 6.3.2. Canada Urinary Tract Infection Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End use
    • 6.3.3. Mexico Urinary Tract Infection Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End use

7. Europe Urinary Tract Infection Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Urinary Tract Infection Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End use
    • 7.3.2. France Urinary Tract Infection Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End use
    • 7.3.3. United Kingdom Urinary Tract Infection Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End use
    • 7.3.4. Italy Urinary Tract Infection Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End use
    • 7.3.5. Spain Urinary Tract Infection Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End use

8. Asia Pacific Urinary Tract Infection Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Urinary Tract Infection Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End use
    • 8.3.2. India Urinary Tract Infection Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End use
    • 8.3.3. Japan Urinary Tract Infection Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End use
    • 8.3.4. South Korea Urinary Tract Infection Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End use
    • 8.3.5. Australia Urinary Tract Infection Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End use

9. Middle East & Africa Urinary Tract Infection Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Urinary Tract Infection Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End use
    • 9.3.2. UAE Urinary Tract Infection Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End use
    • 9.3.3. South Africa Urinary Tract Infection Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End use

10. South America Urinary Tract Infection Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Urinary Tract Infection Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End use
    • 10.3.2. Colombia Urinary Tract Infection Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End use
    • 10.3.3. Argentina Urinary Tract Infection Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Urinary Tract Infection Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. QIAGEN NV
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Accelerate Diagnostics, Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. Danaher Corporation
  • 15.6. Siemens Healthcare GmbH
  • 15.7. Randox Laboratories Ltd.
  • 15.8. Thermo Fisher Scientific, Inc.
  • 15.9. BIOMeRIEUX
  • 15.10. T2 Biosystems, Inc

16. Strategic Recommendations

17. About Us & Disclaimer